ResearcherTel Aviv UniversityNo recent work listed

Yossi Maman

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5039151918. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2023: 1 paper

Papers 1

Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option? Co-author DOI 10.3390/cancers15113049 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Guy Lahat · 1 shared paper, 2023 · strength 0.18
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049 ↗
Joseph M. Klausner · 1 shared paper, 2023 · strength 0.18
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049 ↗
Alex Barenboim · 1 shared paper, 2023 · strength 0.18
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049 ↗
Ido Wolf · 1 shared paper, 2023 · strength 0.18
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049 ↗
Nir Lubezky · 1 shared paper, 2023 · strength 0.18
- Paper Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neo… DOI 10.3390/cancers15113049 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.